

## REMARKS

In the Office Action of May 2, 2007 claims were rejected pursuant to 35 U. S. C. Section 112, 1<sup>st</sup> paragraph on the basis that the specification does not enable the use of the claimed method or combination for treating “any disease” that is treatable by retinoids or responds to the mammals naturally occurring retinoic acid. However, the last Office Action acknowledged that the specification is enabling for the treatment of psoriasis. The present claims were amended, as applicable, to obviate this ground of the rejection. Accordingly, the independent claims 10, 16, 24 and 33 recite only the treatment or delay in the onset of psoriasis. In this connection applicant notes that the present amendment is made in order to simplify and expedite the prosecution and final allowance of the claims. Applicant reserves its right to file one or more continuation/divisional or cip application(s) with claims further directed to the subject matter of the present application.

Claims were also rejected on the basis that in the view of the Examiner, the terminology “a derivative of vitamin A having vitamin A like biological activity” or the terminology “retinoid” are too broad and the use of such compounds in the claimed method is not supported by the specification. To obviate this ground of the rejection, the claims were amended, as applicable, so that they read only upon the use of Vitamin A or retinoic acid as a compound of “Category 2” in the claimed combination.

Claim 18 was amended to add the inadvertently omitted term “or.”

Applicant does not understand clearly the Examiner’s position regarding the breadth of the compounds in Category One, namely compounds that have inhibitory effect on the CP450RAI enzyme of a mammal. Be that as it may, it is applicant’s position that the specification supports the combination of vitamin A or of retinoic acid with any of the

claimed compounds of specific structure in Category One to treat psoriasis. In the Office Action acknowledged that combination of Vitamin A or retinoic acid with the claimed compounds *in vitro* results in inhibition of the CP450RAI enzyme. Such *in vitro* inhibition is an art recognized method of indicating biological activity in *in vivo* systems. For all of the foregoing reasons the present claims are in *prima facie* allowable condition and their early allowance is respectfully solicited.

The Office is respectfully requested to take notice of the undersigned attorney's change of address. A proper "change of address form" has been timely filed, and a copy is presently enclosed.

In the event the Examiner is of the opinion that a telephone conference with the undersigned attorney would materially facilitate the final disposition of this case, she is respectfully requested to telephone the undersigned attorney at the below listed telephone number.

Respectfully submitted

By:

*Gabor L. Szekeres*  
**Gabor L. Szekeres**  
Registration Number 28,675

P.O. Box 27938  
Anaheim Hills, CA 92809  
Tel: 714 944 5778  
Fax: 714 639 4961